The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Future steps in translational medicine for early to late stage lung cancer
Finding predictive biomarkers is a priority for stage 4 disease management, says Giorgio Scagliotti, MD, PhD, of the University of Torino, Torino, Italy, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. New therapeutic agents are on the horizon; however, Dr Scagliotti suggests to look at these in the context of precision medicine rather than generic treatment. Early detection screening methods for lung cancer are also being looked at, while new adjuvant studies should be supplemented with tumor molecular analysis.
